Takayuki Yamamoto

16PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Clinical nutritionAutoimmunityCancer diagnosisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 29, 2026
When nothing else matters: proctectomy for complex perianal Crohn's disease-indications, timing, techniques, and outcomes.

|Apr 29, 2026
Exploring the efficacy and future prospects of nutritional and dietary therapies in Crohn's disease.

|Feb 04, 2026
Leucine-rich alpha-2 glycoprotein as a blood biomarker in inflammatory bowel disease: clinical implications and future perspectives.

Takayuki Yamamoto

|Mar 03, 2025
Clinical features by disease duration in ulcerative colitis-associated cancers.

Hiroshi Miyakita, Seiichiro Yamamoto, Motoi Uchino

|Aug 10, 2023
Editorial: Is vedolizumab the preferred biologic therapy for biologic-naïve patients with ulcerative colitis?

Takayuki Yamamoto

|May 04, 2023
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study.

Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Yohei Mikami

Pageof 3

Frequent Collaborators

4 joint publications

Paulo Gustavo Kotze

1 joint publications

Uri Kopylov

1 joint publications

Katsuyoshi Matsuoka

1 joint publications

Tadakazu Hisamatsu